The Swiss skincare brand, referred to as "Brand X," was established over three years focusing on adult and hormonal acne, a rapidly growing market segment. This company offers a minimalist, science-backed skincare line adhering to Swiss dermatological standards, named the "AcneCare Collection." This includes a two-step regimen: a cleansing gel and a serum, both formulated with critical acne-targeting ingredients such as Zinc PCA, Salicylic Acid, Niacinamide, Magnolia Bark Extract, and Gluconolactone. Distinctively, Brand X has not only developed products but also possesses robust documentation, boasting three independent clinical certifications, including EU and Swiss Cosmetic Safety Reports, which entail comprehensive assessments of their products. They have conducted a Human Patch Test across diverse skin types and passed the ISO 11930 Preservation/Challenge Test. Purchasers of Brand X will acquire around 400 units of finished products, the complete product formulation files, validation documents, and an operational e-commerce platform. Additional assets include a full brand identity kit, marketing materials, and supply chain contacts. Financial records show substantial investment in product development, totaling CHF 29,926 with a current stock value of CHF 11,655. The asking price is CHF 50,000, reflecting the groundwork done over three years. The ideal buyer may be entrepreneurs, beauty distributors, or companies eyeing expansion in the acne treatment market. Brand X is for sale as the founder seeks to pass it to someone with the enthusiasm to scale the brand further. The acquisition will include thorough transitioning support to ensure continuity.